Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil

• Published in: Brain (London, England : 1878) England : 1878), 2013-05, Vol.136 (Pt 5), p.1568-1577
• Main Authors: THOBOIS, Stéphane, LHOMMEE, Eugénie, PELISSIER, Pierre, CHABARDES, Stephan, MERTENS, Patrick, QUESADA, Jean-Louis, BOSSON, Jean-Luc, POLLAK, Pierre, BROUSSOLLE, Emmanuel, KRACK, Paul, KLINGER, Hélène, ARDOUIN, Claire, SCHMITT, Emmanuelle, BICHON, Amélie, KISTNER, Andrea, CASTRIOTO, Anna, JING XIE, FRAIX, Valerie
• Format: Article
• Language: English
• Subjects: Aged; Antiparkinson Agents - pharmacology; Antiparkinson Agents - therapeutic use; Apathy - drug effects; Apathy - physiology; Biological and medical sciences; Dopamine Agonists - pharmacology; Double-Blind Method; Female; Humans; Male; Medical sciences; Middle Aged; Neurology; Neurosurgery; Parkinson Disease - drug therapy; Parkinson Disease - psychology; Piribedil - pharmacology; Piribedil - therapeutic use; Prospective Studies; Receptors, Dopamine D2 - agonists; Receptors, Dopamine D2 - physiology; Receptors, Dopamine D3 - agonists; Receptors, Dopamine D3 - physiology; Skull, brain, vascular surgery; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Treatment Outcome
• ISSN: 0006-8950; 1460-2156
• DOI: 10.1093/brain/awt067

Apathy is one of the most common symptoms encountered in Parkinson's disease, and is defined as a lack of motivation accompanied by reduced goal-directed cognition, behaviour and emotional involvement. In a previous study we have described a delayed withdrawal syndrome after successful motor improvement related to subthalamic stimulation allowing for a major decrease in dopaminergic treatment. This withdrawal syndrome correlated with a diffuse mesolimbic dopaminergic denervation. To confirm our hypothesis of parkinsonian apathy being related to mesolimbic dopaminergic denervation, we performed a randomized controlled study using piribedil, a relatively selective D2/D3 dopamine agonist to treat parkinsonian apathy, using the model of postoperative apathy. A 12-week prospective, placebo-controlled, randomized, double-blinded trial was conducted in 37 patients with Parkinson's disease presenting with apathy (Starkstein Apathy Scale score > 14) following subthalamic nucleus stimulation. Patients received either piribedil up to 300 mg per day (n = 19) or placebo (n = 18) for 12 weeks. The primary end point was the improvement of apathy under treatment, as assessed by the reduction of the Starkstein Apathy Scale score in both treatment groups. Secondary end points included alleviation in depression (Beck Depression Inventory), anxiety (Beck Anxiety Inventory), improvement of quality of life (PDQ39) and anhedonia (Snaith-Hamilton Pleasure Scale). Exploratory endpoints consisted in changes of the Robert Inventory score and Hamilton depression scales. An intention to treat analysis of covariance analysis was performed to compare treatment effects (P < 0.05). The number of premature study dropouts was seven in the placebo and five in the piribedil groups, mostly related to intolerance to hypodopaminergic symptoms. At follow-up evaluation, the apathy score was reduced by 34.6% on piribedil versus 3.2% on placebo (P = 0.015). With piribedil, modifications in the Beck depression and anxiety scores were -19.8% and -22.8%, respectively versus +1.4% and -8.3% with placebo, without reaching significance level. Piribedil led to a trend towards improvement in quality of life (-16.2% versus +6.7% on placebo; P = 0.08) and anhedonia (-49% versus -5.6% on the placebo; P = 0.08). Apathy, assessed by the Robert Inventory score, improved by 46.6% on piribedil and worsened by 2.3% on placebo (P = 0.005). Depression, measured by the Hamilton score, improved in the piribedil group (P